Rocket Pharmaceuticals (RCKT) Assets Average (2016 - 2025)
Rocket Pharmaceuticals (RCKT) has disclosed Assets Average for 10 consecutive years, with $349.2 million as the latest value for Q4 2025.
- Quarterly Assets Average fell 24.19% to $349.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $349.2 million through Dec 2025, down 24.19% year-over-year, with the annual reading at $429.1 million for FY2025, 21.56% down from the prior year.
- Assets Average hit $349.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $394.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $583.7 million in Q1 2021 to a low of $349.2 million in Q4 2025.
- Historically, Assets Average has averaged $486.5 million across 5 years, with a median of $486.4 million in 2022.
- Biggest five-year swings in Assets Average: soared 56.71% in 2021 and later decreased 24.19% in 2025.
- Year by year, Assets Average stood at $513.6 million in 2021, then decreased by 5.66% to $484.5 million in 2022, then rose by 20.23% to $582.6 million in 2023, then decreased by 20.92% to $460.7 million in 2024, then dropped by 24.19% to $349.2 million in 2025.
- Business Quant data shows Assets Average for RCKT at $349.2 million in Q4 2025, $394.5 million in Q3 2025, and $446.0 million in Q2 2025.